Compare · SYM vs TMO
SYM vs TMO
Side-by-side comparison of Symbotic Inc. (SYM) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYM and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $179.14B, about 7.2x SYM ($24.86B).
- Over the past year, SYM is up 43.2% and TMO is up 16.1% - SYM leads by 27.1 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 13 for SYM).
- Both have 25 recent analyst ratings on file.
- Company
- Symbotic Inc.
- Thermo Fisher Scientific Inc
- Price
- $41.24-2.94%
- $482.27-2.41%
- Market cap
- $24.86B
- $179.14B
- 1M return
- -20.29%
- +6.57%
- 1Y return
- +43.24%
- +16.13%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 13
- 17
- Recent ratings
- 25
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest SYM
- Director Kane Charles disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan, acquired 2,000 shares as part of a pre-agreed trading plan and sold $91,980 worth of shares (2,000 units at $45.99) as part of a pre-agreed trading plan, decreasing direct ownership by 85% to 89,852 units (SEC Form 4)
- Director Krasnow Todd sold $94,604 worth of shares (2,000 units at $47.30) as part of a pre-agreed trading plan, disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan and acquired 2,000 shares as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Symbotic Inc.
- SEC Form SD filed by Symbotic Inc.
- Former 10% Owner Svf Sponsor Iii (De) Llc sold $281,819,850 worth of shares (5,590,000 units at $50.41) (SEC Form 4)
- Large owner Softbank Group Corp. sold $281,819,850 worth of shares (5,590,000 units at $50.41) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Symbotic Inc.
- Chief Technology Officer Kuffner James converted options into 9,749 shares and sold $207,501 worth of shares (3,878 units at $53.51), increasing direct ownership by 3% to 185,126 units (SEC Form 4) (withholding tax)
- Director Krasnow Todd gifted 5,000 units of Class V-1 Common Stock, disposed of 19,655 units of Class V-1 Common Stock, acquired 19,655 shares and sold $1,419,675 worth of shares (26,633 units at $53.31), decreasing direct ownership by 98% to 3,367 units (SEC Form 4)
- SEC Form 144 filed by Symbotic Inc.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)